Cell Therapy Technologies Market Trends 2023: Updated Business Statistics and Research Methodology

Comments · 175 Views

Cell Therapy Technologies Market Trends 2023: Updated Business Statistics and Research Methodology

The global cell therapy technologies market is projected to reach USD 8.0 billion by 2027 from USD 4.0 billion in 2022, at a CAGR of 14.6% during the forecast period. Market growth is driven mainly by increasing research in regenerative medicine along with stem cell research, cancer research, and cell biology research.

Request To Download Sample of This Strategic Report @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=213334978

Cell therapy is a type of therapy in which live cells are injected into a patient for the treatment of a number of disorders. It involves the administration of somatic cell preparations for the treatment of diseases or traumatic damages.

This study involved four major activities in estimating the current size of the cell therapy technologies market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research.

Key Market Players

Key players in the Market include Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Danaher Corporation (US), Lonza Group (Switzerland), Sartorius AG (Germany), Terumo BCT (US), Becton, Dickinson and Company (US), Fresenius SE Co. KGaA (Germany), Avantor, Inc. (US), Bio-Techne Corporation (US), Corning Incorporated (US), FUJIFILM Irvine Scientific (US), MaxCyte Inc. (US), Werum IT Solutions GmbH (Germany), RoosterBio Inc. (US), SIRION Biotech GmbH (Germany), TrakCel (UK), L7 Informatics, Inc. (US), Miltenyi Biotec GmbH (Germany), STEMCELL Technologies (Canada), GPI Iberia (Spain), MAK-SYSTEM (US), OrganaBio, LLC (US), IxCells Biotechnology (China), and Wilson Wolf Manufacturing Corporation (US).

The Asia Pacific region is the fastest-growing region of the cell therapy technologies market

The Asia Pacific is estimated to be the fastest-growing segment of the market. The growth of the cell therapy technologies market of the region is mostly driven by their low labor and manufacturing costs, which has drawn huge investments by biopharma giants to these countries. The increasing disposable income, growing prevalence of lifestyle and age-related chronic diseases also contribute to the high growth of the regional market.

For a detailed look at our Table of Contents @   https://www.marketsandmarkets.com/Market-Reports/cell-therapy-technologies-market-213334978.html

This report categorizes the cell therapy technologies market into the following segments and subsegments

By Product

  • Media, Sera, and Reagents
  • Cell Engineering Products
  • Cell Culture Vessels
  • Cell Therapy Equipment
  • Cell Processing Equipment
  • Single-use Equipment
  • Other Equipment
  • Systems and Software
  • Other Products

By Process

  • Cell Processing
  • Cell Preservation, Distribution, and Handling
  • Process Monitoring and Quality Control

By Cell Type

  • T-cells
  • Stem Cells
  • Other Cells

By End User

  • Biopharmaceutical and Biotechnology Companies
  • CROs and CMOs
  • Research Institutes and Cell Banks

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East Africa

Recent Developments

  • Thermo Fisher Scientific launched the first T-cell medium designed specifically for allogeneic cell therapy workflows.
  • Danaher acquired the Biopharma business from General Electric Company's Life Sciences division. The acquisition has led to the formation of a new business named Cytiva, a standalone operating company within Danaher's Life Sciences segment.

Buy-Now this Premium Report @ https://www.marketsandmarkets.com/Purchase/purchase_reportNew.asp?id=213334978

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:

Mr. Aashish Mehra

MarketsandMarkets™ INC.

630 Dundee Road

Suite 430

Northbrook, IL 60062

USA : 1-888-600-6441

sales@marketsandmarkets.com

Comments